サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1790226

パーキンソン病用血液ベースバイオマーカー市場規模、シェア、動向分析レポート：バイオマーカー別、技術別、最終用途別、地域別、セグメント予測、2025年～2033年

Blood-based Biomarker For Parkinson's Disease Market Size, Share & Trends Analysis Report By Biomarker, By Technology, By End Use, By Region, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
パーキンソン病用血液ベースバイオマーカー市場規模、シェア、動向分析レポート：バイオマーカー別、技術別、最終用途別、地域別、セグメント予測、2025年～2033年
出版日: 2025年07月10日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

パーキンソン病用血液ベースバイオマーカー市場概要

パーキンソン病用血液ベースバイオマーカーの世界市場規模は、2024年に1億1,779万米ドルと推定され、2033年には3億5,087万米ドルに達し、2025～2033年のCAGRは19.25%で成長すると予測されています。同市場は、世界のパーキンソン病有病率の上昇、神経診断学やバイオマーカー研究に対する投資の増加、プロテオミクスやゲノム技術の進歩などを背景に大きな伸びを示しています。

世界疾病負担調査2021のデータによると、2050年までにパーキンソン病の罹患者は年齢・性別を問わず全世界で約2,520万人に達し、2021年に記録された数字と比較して112%増加すると研究者は予測しています。パーキンソン病（PD）の世界の罹患率は、特に北米、欧州、アジア太平洋の一部で、高齢者が増加しています。パーキンソン病（PD）の罹患率は加齢とともに著しく増加し、特に65歳以上では加齢がこの疾患の主要な危険因子となっています。いくつかの研究では、PDはすべての年齢層で女性よりも男性に多くみられることが一貫して示されています。PDの罹患率の増加は、世界の高齢化の進展と密接に相関しており、人口動態の変化が今後数十年間も患者数を増加させることを示唆しています。平均寿命が延びるにつれて、パーキンソン病の負担は増大すると予想されます。IHME Global Burden of Disease（2024年）によると、様々な大陸におけるパーキンソン病の症例を示しています。

このような患者数の増加により、早期で正確かつ低侵襲な診断ツールの緊急需要が高まっています。血液ベースバイオマーカーは、従来型臨床診断や画像診断に代わる有望な手段となります。神経変性疾患に対する認識が世界的に高まるにつれ、利用しやすい診断へのニーズも高まっており、血液ベースバイオマーカーは、パーキンソン病の負担増に対応し、早期の治療介入を支援するための重要なソリューションとして位置付けられています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 パーキンソン病用血液ベースバイオマーカー市場の変動動向と展望

  • 市場系統の展望
    • 親市場
    • 補助市場
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
    • 市場機会分析
    • 市場課題分析
  • パーキンソン病用血液ベースバイオマーカー市場分析ツール
    • 産業分析-ポーターのファイブフォース分析
    • PESTEL分析
    • 規制の枠組み
    • 価格分析
    • 償還シナリオ
    • 技術の進歩

第4章 パーキンソン病市場における血液バイオマーカー：バイオマーカー別、推定・動向分析

  • セグメントダッシュボード
  • パーキンソン病用血液ベースバイオマーカー市場：バイオマーカー変動分析
  • パーキンソン病用血液ベースバイオマーカー市場規模と動向分析（バイオマーカー別、2021～2033年）
  • タンパク質バイオマーカー
  • 炎症マーカー
  • 代謝マーカー
  • トランスクリプトミクス/miRNA
  • その他

第5章 パーキンソン病用血液ベースバイオマーカー市場：動物タイプ別、推定・動向分析

  • セグメントダッシュボード
  • パーキンソン病用血液ベースバイオマーカー市場：動物タイプ変動分析
  • パーキンソン病血液バイオマーカー市場規模と動向分析（動物タイプ別、2021～2033年）
  • 犬
  • 猫
  • 馬
  • その他

第6章 パーキンソン病用血液ベースバイオマーカー市場：技術別、推定・動向分析

  • セグメントダッシュボード
  • パーキンソン病用血液ベースバイオマーカー市場：技術変動分析
  • パーキンソン病用血液ベースバイオマーカー市場規模と動向分析（技術別、2021～2033年）
  • ELISA/免疫測定
  • マルチプレックスプラットフォーム
  • NGS/qPCR（遺伝学）
  • 質量分析
  • その他

第7章 パーキンソン病用血液ベースバイオマーカー市場：最終用途別、推定・動向分析

  • セグメントダッシュボード
  • パーキンソン病用血液ベースバイオマーカー市場：最終用途変動分析
  • パーキンソン病用血液ベースバイオマーカー市場規模と動向分析（最終用途別、2021～2033年）
    • 学術ラボ
    • 製薬/バイオテクノロジー
    • 病院
    • 臨床診断ラボ
    • その他

第8章 パーキンソン病用血液ベースバイオマーカー市場：地域別、推定・動向分析

  • 地域ダッシュボード
  • パーキンソン病用血液ベースバイオマーカー市場シェア（地域別、2024年と2033年）
  • 地域展望
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第9章 競合情勢

  • 市場参入企業の分類
  • 企業の市況分析/ヒープマップ分析
  • 企業プロファイル
    • IDEXX Laboratories, Inc.
    • Abbott Laboratories
    • ACOBIOM
    • Alseres Pharmaceuticals
    • Banyan Biomarkers
    • Bio-Rad Laboratories
    • DiaGenic ASA
    • Johnson & Johnson
    • Merck KGaA
    • QIAGEN
  • 戦略マッピング
    • 合併と買収
    • パートナーシップとコラボレーション
    • 製品発売
    • その他
  • その他の主要参入企業一覧
図表

List of tables

  • Table 1 List of secondary sources
  • Table 2 Blood-based Biomarker For Parkinson's Disease Market, by region, 2021 - 2033 (USD Million)
  • Table 3 Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 4 Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 5 Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 6 North America Blood-based Biomarker For Parkinson's Disease Market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 8 North America Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 9 North America Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 10 U.S. Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 11 U.S. Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 12 U.S. Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 13 Canada Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 14 Canada Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 15 Canada Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 16 Mexico Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 17 Mexico Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 18 Mexico Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 19 Europe Blood-based Biomarker For Parkinson's Disease Market, by country, 2021 - 2033 (USD Million)
  • Table 20 Europe Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 21 Europe Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 22 Europe Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 23 Germany Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 24 Germany Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 25 Germany Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 26 UK Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 27 UK Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 28 UK Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 29 France Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 30 France Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 31 France Blood-based Biomarker For Parkinson's Disease Market, by Type, 2021 - 2033 (USD Million)
  • Table 32 Italy Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 33 Italy Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 34 Italy Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 35 Spain Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 36 Spain Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 37 Spain Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 38 Denmark Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 39 Denmark Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 40 Sweden Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 41 Sweden Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 42 Sweden Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 43 Norway Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 44 Norway Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 45 Norway Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific Blood-based Biomarker For Parkinson's Disease Market, by country, 2021 - 2033 (USD Million)
  • Table 47 Asia Pacific Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 50 China Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 51 China Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 52 China Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 53 Japan Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 54 Japan Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 55 Japan Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 56 India Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 57 India Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 58 India Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 59 South Korea Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 60 South Korea Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 61 South Korea Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 62 Australia Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 63 Australia Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 64 Australia Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 65 Thailand Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 66 Thailand Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 67 Thailand Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 68 Latin America Blood-based Biomarker For Parkinson's Disease Market, by country, 2021 - 2033 (USD Million)
  • Table 69 Latin America Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 70 Latin America Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 71 Latin America Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 72 Brazil Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 73 Brazil Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 74 Brazil Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 75 Argentina Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 76 Argentina Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 77 Argentina Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 78 MEA Blood-based Biomarker For Parkinson's Disease Market, by country, 2021 - 2033 (USD Million)
  • Table 79 MEA Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 80 MEA Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 81 MEA Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 82 South Africa Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 83 South Africa Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 84 South Africa Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 85 Saudi Arabia Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 86 Saudi Arabia Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 88 UAE Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 89 UAE Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 90 UAE Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 91 Kuwait Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 92 Kuwait Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 94 Company Overview
  • Table 95 Product Benchmarking
  • Table 96 Financial Performance
  • Table 97 Strategic Initiatives

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Blood-based Biomarker For Parkinson's Disease Market revenue, 2021-2033 (USD Million)
  • Fig. 10 Blood-based Biomarker For Parkinson's Disease Market snapshot
  • Fig. 11 Blood-based Biomarker For Parkinson's Disease Market driver impact
  • Fig. 12 Blood-based Biomarker For Parkinson's Disease Market restraint impact
  • Fig. 13 Blood-based Biomarker For Parkinson's Disease biomarker key takeaways (USD Million)
  • Fig. 14 Blood-based Biomarker For Parkinson's Disease Market: biomarker movement analysis
  • Fig. 15 Protein biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 16 Inflammatory markers market, 2021 - 2033 (USD Million)
  • Fig. 17 Metabolic markers market, 2021 - 2033 (USD Million)
  • Fig. 18 Transcriptomic/miRNA market, 2021 - 2033 (USD Million)
  • Fig. 19 Others market, 2021 - 2033 (USD Million)
  • Fig. 20 Blood-based Biomarker For Parkinson's Disease technology key takeaways (USD Million)
  • Fig. 21 Blood-based Biomarker For Parkinson's Disease Market: technology movement analysis
  • Fig. 22 ELISA/Immunoassay market, 2021 - 2033 (USD Million)
  • Fig. 23 Multiplex platforms market, 2021 - 2033 (USD Million)
  • Fig. 24 NGS/qPCR (genetic) market, 2021 - 2033 (USD Million)
  • Fig. 25 Mass spectrometry market, 2021 - 2033 (USD Million)
  • Fig. 26 Others market, 2021 - 2033 (USD Million)
  • Fig. 27 Blood-based Biomarker For Parkinson's Disease Market by End Use key takeaways (USD Million)
  • Fig. 28 Blood-based Biomarker For Parkinson's Disease Market: by End Use movement analysis
  • Fig. 29 Academic/Research Labs market, 2021 - 2033 (USD Million)
  • Fig. 30 Pharmaceutical /Biotech market, 2021 - 2033 (USD Million)
  • Fig. 31 Hospitals market, 2021 - 2033 (USD Million)
  • Fig. 32 Clinical Diagnostic Labs market, 2021 - 2033 (USD Million)
  • Fig. 33 Others market, 2021 - 2033 (USD Million)
  • Fig. 34 Regional market place: Key takeaways
  • Fig. 35 Regional outlook, 2024 & 2033
  • Fig. 36 North America Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 38 Canada Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 39 Mexico Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 40 Europe Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 41 UK Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 42 Germany Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 43 France Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 44 Italy Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 45 Spain Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 46 Denmark Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 47 Sweden Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 48 Norway Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 50 Japan Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 51 China Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 52 India Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 53 Australia Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 54 South Korea Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 55 Thailand Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 56 Latin America Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 57 Brazil Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 58 Argentina Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 59 MEA Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 60 South Africa Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 61 Saudi Arabia Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 62 UAE Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 63 Kuwait Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 64 Market participant categorization
目次
Product Code: GVR-4-68040-667-9

Blood-based Biomarker For Parkinson's Disease Market Summary

The global blood-based biomarker for Parkinson's disease market size was estimated at USD 117.79 million in 2024 and is projected to reach USD 350.87 million by 2033, growing at a CAGR of 19.25% from 2025 to 2033. The market is exhibiting significant growth driven by rising prevalence of Parkinson's disease worldwide, increasing investment in neurology diagnostics and biomarker research and advances in proteomics and genomic technologies.

The data from the global burden of disease study 2021, researchers project that by 2050, Parkinson's disease will affect approximately 25.2 million people worldwide across all ages and sexes, an increase of 112% compared to the numbers recorded in 2021. The global incidence of Parkinson's disease (PD) is increasing due to geriatric populations, particularly in North America, Europe, and parts of Asia-Pacific. Parkinson's disease (PD) incidence rates increase significantly with age, particularly among individuals aged 65 and older, making age the primary risk factor for the condition. Some studies consistently show that PD is more prevalent in males than females across all age groups. The rising incidence of PD closely correlates with the expanding aging population worldwide, suggesting that demographic shifts will continue to drive up the number of cases in the coming decades. As life expectancy increases, the burden of Parkinson's disease is expected to grow. The graph below depicts cases of Parkinson's disease in various continents according to the IHME Global Burden of Disease (2024):

This growing patient pool drives urgent demand for early, accurate and minimally invasive diagnostic tools. Blood-based biomarkers offer a promising alternative to traditional clinical and imaging-based diagnosis, which often detects PD only in later stages. As awareness of neurodegenerative diseases increases globally, so does the need for accessible diagnostics, positioning blood-based biomarkers as a critical solution to meet the rising burden of Parkinson's and support earlier therapeutic intervention.

Blood-based Biomarker For Parkinson's Disease Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the blood-based biomarker for Parkinson's disease market report based on technology, biomarker, end use, and region:

  • Biomarker Outlook (Revenue, USD Million, 2021-2033)
  • Protein biomarkers
  • Inflammatory markers
  • Metabolic markers
  • Transcriptomic/miRNA
  • Others
  • Technology Outlook (Revenue, USD Million, 2021-2033)
  • ELISA/Immunoassay
  • Multiplex platforms
  • NGS/qPCR (genetic)
  • Mass spectrometry
  • Others
  • End Use Outlook (Revenue, USD Million, 2021-2033)
  • Academic/Research Labs
  • Pharmaceutical / Biotech (for Clinical Trials)
  • Hospitals
  • Clinical Diagnostic Labs
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • India
    • China
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Global Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Blood-based Biomarker for Parkinson's Disease Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising prevalence of Parkinson's disease worldwide
      • 3.2.1.2. Increasing investment in neurology diagnostics and biomarker research
      • 3.2.1.3. Advances in proteomics and genomic technologies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Costs and Technical Complexity Restrict Accessibility in Low-Resource Settings
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. Blood-based Biomarker For Parkinson's Disease Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
    • 3.3.3. Regulatory Framework
    • 3.3.4. Pricing Analysis
    • 3.3.5. Reimbursement Scenario
    • 3.3.6. Technological Advancements

Chapter 4. Blood-based Biomarker for Parkinson's Disease Market: Biomarker Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Blood-based Biomarker For Parkinson's Disease Market: Biomarker Movement Analysis
  • 4.3. Blood-based Biomarker For Parkinson's Disease Market Size & Trend Analysis, by Biomarker, 2021 to 2033 (USD Million)
  • 4.4. Protein biomarkers
    • 4.4.1. Protein biomarkers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Inflammatory markers
    • 4.5.1. Inflammatory markers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Metabolic markers
    • 4.6.1. Metabolic markers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Transcriptomic/miRNA
    • 4.7.1. Transcriptomic/miRNA Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Blood-based Biomarker For Parkinson's Disease Market: Animal Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Blood-based Biomarker For Parkinson's Disease Market: Animal type Movement Analysis
  • 5.3. Blood-based Biomarker For Parkinson's Disease Market Size & Trend Analysis, by animal type, 2021 to 2033 (USD Million)
  • 5.4. Dogs
    • 5.4.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Cats
    • 5.5.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Horses
    • 5.6.1. Horses Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Blood-based Biomarker for Parkinson's Disease Market: Technology Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Blood-based Biomarker for Parkinson's Disease Market: Technology Movement Analysis
  • 6.3. Blood-based Biomarker for Parkinson's Disease Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
  • 6.4. ELISA/Immunoassay
    • 6.4.1. ELISA/Immunoassay Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Multiplex platforms
    • 6.5.1. Multiplex platforms Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. NGS/qPCR (genetic)
    • 6.6.1. NGS/qPCR (genetic) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Mass spectrometry
    • 6.7.1. Mass spectrometry Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Blood-based Biomarker for Parkinson's Disease Market: By End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Blood-based Biomarker for Parkinson's Disease Market: By End Use Movement Analysis
  • 7.3. Blood-based Biomarker for Parkinson's Disease Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
    • 7.3.1. Academic/Research Labs
      • 7.3.1.1. Academic/Research Labs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. Pharmaceutical / Biotech
      • 7.3.2.1. Pharmaceutical / Biotech Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Hospitals
      • 7.3.3.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Clinical Diagnostic Labs
      • 7.3.4.1. Clinical Diagnostic Labs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.5. Others
      • 7.3.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Blood-based Biomarker for Parkinson's Disease Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Dashboard
  • 8.2. Blood-based Biomarker for Parkinson's Disease Market Share, By Region, 2024 & 2033 (USD Million)
  • 8.3. Regional Outlook
  • 8.4. North America
    • 8.4.1. North America Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. U.S. Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. Canada Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Mexico Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. UK Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Germany Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. France Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. Italy Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Spain Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory framework/ reimbursement structure
      • 8.5.7.3. Competitive scenario
      • 8.5.7.4. Denmark Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory framework/ reimbursement structure
      • 8.5.8.3. Competitive scenario
      • 8.5.8.4. Sweden Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory framework/ reimbursement structure
      • 8.5.9.3. Competitive scenario
      • 8.5.9.4. Norway Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Japan Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. China Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. India Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Australia Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. South Korea Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Thailand Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Brazil Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. Argentina Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Middle East & Africa
    • 8.8.1. Middle East & Africa Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. South Africa Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory framework/ reimbursement structure
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Saudi Arabia Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory framework/ reimbursement structure
      • 8.8.4.3. Competitive scenario
      • 8.8.4.4. UAE Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory framework/ reimbursement structure
      • 8.8.5.3. Competitive scenario
      • 8.8.5.4. Kuwait Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Position Analysis/ Heap Map Analysis
  • 9.3. Company Profiles
    • 9.3.1. IDEXX Laboratories, Inc.
      • 9.3.1.1. Participant's Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Abbott Laboratories
      • 9.3.2.1. Participant's Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. ACOBIOM
      • 9.3.3.1. Participant's Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Alseres Pharmaceuticals
      • 9.3.4.1. Participant's Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Banyan Biomarkers
      • 9.3.5.1. Participant's Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Bio-Rad Laboratories
      • 9.3.6.1. Participant's Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. DiaGenic ASA
      • 9.3.7.1. Participant's Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Johnson & Johnson
      • 9.3.8.1. Participant's Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Merck KGaA
      • 9.3.9.1. Participant's Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. QIAGEN
      • 9.3.10.1. Participant's Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Product Benchmarking
      • 9.3.10.4. Strategic Initiatives
      • 9.3.10.5. Quanterix
      • 9.3.10.6. Participant's Overview
      • 9.3.10.7. Financial Performance
      • 9.3.10.8. Product Benchmarking
      • 9.3.10.9. Strategic Initiatives
      • 9.3.10.10. Thermo Fisher Scientific
      • 9.3.10.11. Participant's Overview
      • 9.3.10.12. Financial Performance
      • 9.3.10.13. Product Benchmarking
      • 9.3.10.14. Strategic Initiatives
  • 9.4. Strategy Mapping
    • 9.4.1. Mergers & Acquisitions
    • 9.4.2. Partnerships & Collaborations
    • 9.4.3. Product launch
    • 9.4.4. Others
  • 9.5. List of other key players